Monte Rosa Therapeutics Announces Positive Phase 1 Data for MRT-8102

What Happened
Monte Rosa Therapeutics (GLUE) announced on October 1, 2026 that its GFORCE‑1 Phase 1 study of MRT‑8102, a NEK7‑directed molecular glue degrader targeting the NLRP3 inflammasome, produced positive biomarker and safety results. The company also hosted a conference call/webcast and posted a presentation; the press release and presentation are furnished as Exhibits 99.1 and 99.2 to the 8‑K.

Key Details

• GFORCE‑1 enrolled 108 obese subjects with elevated cardiovascular disease (CVD) risk; randomized to MRT‑8102 5 mg, 20 mg, 40 mg once daily, or placebo for 4 weeks dosing + 4 weeks follow‑up.
• MRT‑8102 produced robust NEK7 degradation with a median reduction of ~80–90% across all dose levels.
• Biomarkers: substantial reductions in local plaque drivers and systemic inflammatory markers; median lipoprotein(a) (Lp[a]) fell 24% (comparable to PCSK9 inhibitors). Unlike IL‑6(R) blockade, MRT‑8102 did not increase LDL‑C or triglycerides.
• Safety: well tolerated over 8 weeks with no serious adverse events (SAEs); treatment‑emergent adverse events (TEAEs) occurred in 33% of MRT‑8102 subjects vs 30% placebo; no evidence of increased infection risk.
• Planned Phase 2 program: GFORCE‑2 (Phase 2b in stable coronary artery disease) expected H1 2027 pending regulatory feedback and completion of long‑term preclinical toxicology; GEMINI‑1 (gout) expected Q4 2026–Q1 2027 with initial data H2 2027; GALAXY‑1 (hidradenitis suppurativa) expected H1 2027.

Why It Matters
For investors, the filing signals that MRT‑8102 achieved strong target engagement and meaningful biomarker changes in a Phase 1 cohort, with an acceptable short‑term safety profile—supporting the company’s plan to advance into multiple Phase 2 studies across cardiovascular and inflammatory indications. These are early, biomarker‑driven results (not clinical outcome data); the company notes forward‑looking risks and the need for additional preclinical and clinical work before efficacy and safety are confirmed.